Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Smith & Nephew plc (SNN) Price & Performance

Amylx Pharmaceuticals IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Smith & Nephew plc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 4.8× Amylx Pharmaceuticals Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXSNN
Market Cap
$2.64B$12.54B
Sector
HealthHealth
52-Week High
$24.19$38.70
52-Week Low
$7.82$28.73
Enterprise Value
$2.39B$15.57B
Dividend Yield
2.65%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN